Immune Pharmaceuticals Inc (fka IMNPQ)

[itsabouttime]

Perhaps another Jazz Pharmaceuticals will be in the making. IMNP was comparable in focus as mentioned in interview then expanded through partnership to present $114.00 PPS. Need to line up partnership.

Partnerships historically happen in Phase 111.

(NASDAQ:IMNP), after the company announced its plan to submit the final protocol for an international pivotal Phase III trial of Ceplene in combination with low-dose IL-2 for the remission maintenance of acute myeloid leukemia (AML) patients.

Bernardino wrote, “The decision was based on the FDA’s latest guidance received by Immune regarding Ceplene’s future regulatory pathway in the U.S. The new Phase III trial design, which Immune intends to submit in early 2017, will measure overall survival (OS) as the primary endpoint.